Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: A pooled analysis of clinical evidence

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Sun, Wenjie ^a   Leong, Cheng N ^b   Zhang, Zhen ^a   Lu, Jiade J ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RESEARCH; CELIAC ARTERY; COMPUTER ASSISTED RADIOTHERAPY; EMBASE; HEPATIC ARTERY; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; JAPAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDLINE; PANCREAS CANCER; PANCREAS RESECTION; PARAAORTIC LYMPH NODE; PROBABILITY; SPLEEN ARTERY; SUPERIOR MESENTERIC ARTERY; TUMOR LOCALIZATION; CANCER STAGING; FEMALE; LYMPH NODE; MALE; META ANALYSIS; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; RADIATION DOSE; RADIATION EXPOSURE;

FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 77950828733     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-28     Document Type: Article

References (55)

1. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 2004, 28:219-230. 10.1097/00006676-200404000-00002, 15084961.
2. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, Evans RG. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990, 66:56-61. 10.1002/1097-0142(19900701)66:1<56::AID-CNCR2820660112>3.0.CO;2-6, 2354408.
3. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resected adenocarcinoma of the pancreas--616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000, 4:567-579. 10.1016/S1091-255X(00)80105-5, 11307091.
4. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?. Ann Surg 1995, 221:59-66. 10.1097/00000658-199501000-00007, 1234495, 7826162.
5. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
6. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776-782. 10.1097/00000658-199912000-00006, 1420941, 10615932.
7. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology group Study. J Clin Oncol 1998, 16:317-323.
8. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981, 48:1705-1710. 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4, 7284971.
9. Gastrointestinal Tumor Study Group Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988, 80:751-755. 10.1093/jnci/80.10.751, 2898536, Gastrointestinal Tumor Study Group.
10. Chmura SJ, Heimann R. Normal tissue toxicity using intensity modulated radiation therapy(IMRT) in pancreatic cancer and cholangiocarcinoma. [Abstract] Proc Am Soc Clin Oncol 2001, 20:1093.
11. Spalding AC, Jee KW, Vineberg K, Jablonowski M, Fraass BA, Pan CC, Lawrence TS, Haken RK, Ben-Josef E. Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 2007, 34:521-529. 10.1118/1.2426403, 17388169.
12. Brown MW, Ning H, Arora B, Albert PS, Poggi M, Camphausen K, Citrin D. A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2006, 65:274-283.
13. Wieland P, Dobler B, Mai S, Hermann B, Tiefenbacher U, Steil V, Wenz F, Lohr F. IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int J Radiat Oncol Biol Phys 2004, 59:1236-1244. 10.1016/j.ijrobp.2004.02.051, 15234061.
14. Japan Pancreas Society Classification of pancreatic carcinoma. 2003, Tokyo: Kanehara, 2nd English, Japan Pancreas Society.
15. Ishikawa O, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H, Imaoka S, Iwanaga T. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988, 208:215-220. 10.1097/00000658-198808000-00014, 1493620, 2840866.
16. Brunner TB, Merkel S, Grabenbauer GG, Meyer T, Baum U, Papadopoulos T, Sauer R, Hohenberger W. Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. Int J Radiat Oncol Biol Phys 2005, 62:1021-1029.
17. Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Ueno K, Tajima H, Elnemr A, Miwa K. Analysis of paraaortic lymph node involvement in pancreatic carcinoma: a significant indication for surgery?. Cancer 1999, 85:583-590. 10.1002/(SICI)1097-0142(19990201)85:3<583::AID-CNCR8>3.0.CO;2-J, 10091731.
18. Sierzega M, Popiela T, Kulig J, Nowak K. The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas 2006, 33:240-245. 10.1097/01.mpa.0000235306.96486.2a, 17003644.
19. Nagakawa T, Kobayashi H, Ueno K, Ohta T, Kayahara M, Mori K, Nakano T, Takeda T, Konishi I, Miyazaki I. The pattern of lymph node involvement in carcinoma of the head of the pancreas. A histologic study of the surgical findings in patients undergoing extensive nodal dissections. Int J Pancreatol 1993, 13:15-22.
20. Nagakawa T, Kobayashi H, Ueno K, Ohta T, Kayahara M, Miyazaki I. Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas. Cancer 1994, 73:1155-1162. 10.1002/1097-0142(19940215)73:4<1155::AID-CNCR2820730406>3.0.CO;2-H, 8313317.
21. Capussotti L, Massucco P, Ribero D, Viganò L, Muratore A, Calgaro M. Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg 2003, 138:1316-1322. 10.1001/archsurg.138.12.1316, 14662531.
22. Cubilla AL, Fortner J, Fitzgerald PJ. Lymph node involvement in carcinoma of the head of the pancreas area. Cancer 1978, 41:880-887. 10.1002/1097-0142(197803)41:3<880::AID-CNCR2820410315>3.0.CO;2-J, 638975.
23. Nakao A, Harada A, Nonami T, Kaneko T, Nomoto S, Koyama H, Kanazumi N, Nakashima N, Takagi H. Lymph node metastasis in carcinoma of the body and tail of the pancreas. Br J Surg 1997, 84:1090-1092. 10.1002/bjs.1800840813, 9278647.
24. Nagai H, Kuroda A, Morioka Y. Lymphatic and local spread of T1 and T2 pancreatic cancer. A study of autopsy material. Ann Surg 1986, 204:65-71. 10.1097/00000658-198607000-00009, 1251224, 3015059.
25. Kayahara M, Nagakawa T, Futagami F, Kitagawa H, Ohta T, Miyazaki I. Lymphatic flow and neural plexus invasion associated with carcinoma of the body and tail of the pancreas. Cancer 1996, 78:2485-2491. 10.1002/(SICI)1097-0142(19961215)78:12<2485::AID-CNCR6>3.0.CO;2-J, 8952555.
26. Kayahara M, Nagakawa T, Kobayashi H, Mori K, Nakano T, Kadoya N, Ohta T, Ueno K, Miyazaki I. Lymphatic flow in carcinoma of the head of the pancreas. Cancer 1992, 70:2061-2066. 10.1002/1097-0142(19921015)70:8<2061::AID-CNCR2820700808>3.0.CO;2-V, 1327485.
27. Yoshida T, Matsumoto T, Sasaki A, Shibata K, Aramaki M, Kitano S. Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. Am J Surg 2004, 187:736-740. 10.1016/j.amjsurg.2003.07.031, 15191867.
28. Sakai M, Nakao A, Kaneko T, Takeda S, Inoue S, Kodera Y, Nomoto S, Kanazumi N, Sugimoto H. Para-aortic lymph node metastasis in carcinoma of the head of the pancreas. Surgery 2005, 137:606-611. 10.1016/j.surg.2005.02.009, 15933626.
29. Gerdes B, Ramaswamy A, Bartsch DK, Rothmund M. Peripyloric lymph node metastasis is a rare condition in carcinoma of the pancreatic head. Pancreas 2005, 31:88-92. 10.1097/01.mpa.0000168221.97967.98, 15968254.
30. Ishikawa O, Ohigashi H, Sasaki Y, Kabuto T, Furukawa H, Nakamori S, Imaoka S, Iwanaga T, Kasugai T. Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy. Surgery 1997, 121:244-249. 10.1016/S0039-6060(97)90352-4, 9068665.
31. Kayahara M, Nagakawa T, Ueno K, Ohta T, Tsukioka Y, Miyazaki I. Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion. Surgery 1995, 117:616-623. 10.1016/S0039-6060(95)80003-4, 7778025.
32. Kocher HM, Sohail M, Benjamin IS, Patel AG. Technical limitations of lymph node mapping in pancreatic cancer. Eur J Surg Oncol 2007, 33:887-891.
33. Hazard L. The role of radiation therapy in pancreas cancer. Gastrointest Cancer Res 2009, 3:20-28. 2661119, 19343134.
34. Withers HR, Peters LJ, Taylor JM. Dose-response relationship for radiation therapy of subclinical disease. Int J Radiat Oncol Biol Phys 1995, 31:353-359.
35. Willett CG, Clark JW. Update on combined-modality treatment options for pancreatic cancer. Oncology 2003, 17:29-36.
36. Lemke AJ, Niehues SM, Hosten N, Amthauer H, Boehmig M, Stroszczynski C, Rohlfing T, Rosewicz S, Felix R. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients. J Nucl Med 2004, 45:1279-1286.
37. De Gaetano AM, Vecchioli A, Minordi LM, Parrella A, Gaudino S, Masselli G, Savino G. Role of diagnostic imaging in abdominal lymphadenopathy. Rays 2000, 25:463-484.
38. Hanbidge AE. Cancer of the pancreas: the best image for early detection--CT, MRI, PET or US?. Can J Gastroenterol 2002, 16:101-105.
39. Yu H, Caldwell C, Mah K, Poon I, Balogh J, MacKenzie R, Khaouam N, Tirona R. Automated radiation targeting in head-and-neck cancer using region-based texture analysis of PET and CT images. Int J Radiat Oncol Biol Phys 2009, 75:618-625.
40. Geets X, Lee JA, Castadot P, Bol A, Grégoire V. Potential place of FDG-PET for the GTV delineation in head and neck and lung cancers. Cancer Radiother 2009, 13:594-599.
41. Yu J, Li X, Xing L, Mu D, Fu Z, Sun X, Sun X, Yang G, Zhang B, Sun X, Ling CC. Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study. Int J Radiat Oncol Biol Phys 2009, 75:1468-1474.
42. Strobel K, Heinrich S, Bhure U, Soyka J, Veit-Haibach P, Pestalozzi BC, Clavien PA, Hany TF. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 2008, 49:1408-1413. 10.2967/jnumed.108.051466, 18703604.
43. Sendler A, Avril N, Helmberger H, Stollfuss J, Weber W, Bengel F, Schwaiger M, Roder JD, Siewert JR. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000, 24:1121-1129. 10.1007/s002680010182, 11036292.
44. Kitajima K, Murakami K, Yamasaki E, Kaji Y, Shimoda M, Kubota K, Suganuma N, Sugimura K. Performance of Integrated FDG-PET/Contrast-enhanced CT in the Diagnosis of Recurrent Pancreatic Cancer: Comparison with Integrated FDG-PET/Non-contrast-enhanced CT and Enhanced CT. Mol Imaging Biol 2009,
45. Manabe T, Ohshio G, Baba N, Miyashita T, Asano N, Tamura K, Yamaki K, Nonaka A, Tobe T. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 1989, 64:1132-1137. 10.1002/1097-0142(19890901)64:5<1132::AID-CNCR2820640528>3.0.CO;2-V, 2547508.
46. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Klöppel G, Dhaene K, Michelassi F. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas. Ann Surg 1998, 228:508-517. 10.1097/00000658-199810000-00007, 1191525, 9790340.
47. Yeo CJ, Cameron JL, Sohn TA, Coleman J, Sauter PK, Hruban RH, Pitt HA, Lillemoe KD. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Comparison of morbidity and mortality and short-term outcome. Ann Surg 1999, 229:613-624. 10.1097/00000658-199905000-00003, 1420805, 10235519.
48. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N, Sargent DJ. Pancreas Cancer Working Group: A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005, 138:618-630. 10.1016/j.surg.2005.06.044, 16269290.
49. Yoshida T, Matsumoto T, Sasaki A, Shibata K, Aramaki M, Kitano S. Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. Am J Surg 2004, 187:736-740. 10.1016/j.amjsurg.2003.07.031, 15191867.
50. Bussels B, Goethals L, Feron M, Bielen D, Dymarkowski S, Suetens P, Haustermans K. Respiration-induced movement of the upper abdominal organs: A pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer. Radiother Oncol 2003, 68:69-74. 10.1016/S0167-8140(03)00133-6, 12885454.
51. Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Lahoti S, Vauthey JN, Janjan NA. Combining gemcitabine with radiation in pancreatic cancer: Understanding important variables influencing the therapeutic index. Semin Oncol 2001, 28(3 Suppl 10):25-33. 10.1053/sonc.2001.22536, 11510031.
52. Brunner TB, Grabenbauer GG, Klein P, Baum U, Papadopoulos T, Bautz W, Hohenberger W, Sauer R. Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003, 55:144-153. 10.1016/S0360-3016(02)03818-X, 12504047.
53. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
54. Bai YR, Wu GH, Guo WJ, Wu XD, Yao Y, Chen Y, Zhou RH, Lu DQ. Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study. World J Gastroenterol 2003, 9:2561-2564.
55. Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF, McDermott P, Burmeister J, Bossenberger T, Philip PA. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 59:454-459.